Physician Communications

Aspen wishes to advise you that responsibility for LIVIAL® (tibolone) will be returning to MSD, who are the Sponsor of this product, effective 1 June 2018.

Aspen Pharmacare wish to advise that Di-Gesic will be discontinued effective 1 April 2018. Regrettably, Aspen has been unable to procure suitable Active Pharmaceutical Ingredient to continue manufacture and supply of Di-Gesic in Australia. The Therapeutic Goods Administration has been notified and the product has been placed on the “Medicine Shortages Information” list. Please see…

Aspen is pleased to advise that both presentations of ASPEN Fentanyl injection are back in stock in Australia and are available to order from your wholesaler. • ASPEN Fentanyl 100 micrograms per 2 mL solution for injection x 5 Amps are available with no supply restrictions. • ASPEN Fentanyl 500 micrograms per 10 mL solution…

Dear Ophthalmologist, Aspen Pharma Pty Ltd wishes to advise that it is currently experiencing supply problems with Atropt. New stock is expected to arrive in Australia in mid – late August and should reach the wholesalers soon thereafter. However, it is likely the market will be completely out of stock for a short period of…

Palatability of oral antibiotic suspension is important and may be a factor in determining improved compliance in paediatric patients. Aspen’s comprehensive range of antibiotic suspensions are available as pleasant tasting paediatric formulations: